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The Multiple Sclerosis-Fatigue Self– 
Efficacy (MS-FSE) scale: initial 
validation
Sarah Thomas1, Paula Kersten2 and Peter W Thomas1
Abstract
Objective: To examine the validity and sensitivity to change of the Multiple Sclerosis-Fatigue Self-Efficacy 
scale.
Design: A validation study nested within a randomized controlled trial.
Setting: Community setting.
Participants: Adults with a clinically definite diagnosis of multiple sclerosis and significant fatigue taking 
part in a randomized controlled trial evaluating a group-based fatigue management programme (FACETS) 
for people with multiple sclerosis (N=164).
Main measures: The 9-item Multiple Sclerosis-Fatigue Self-Efficacy scale was completed at baseline, 1-, 
4- and 12 months post intervention. Validity, internal consistency and sensitivity to change were examined 
using classical test theory and Rasch analysis.
Results: Item 3 was unanswered by 6% of respondents as they did not know any other people with 
multiple sclerosis; remaining analyses were carried out with this item deleted. All response choices were 
utilised, no floor or ceiling effects were evident and there were few missing responses. Cronbach’s alphas 
were high (baseline, 0.89; follow-up 1, 0.93; follow-up 2, 0.94; follow-up 3, 0.90). The Multiple Sclerosis-
Fatigue Self-Efficacy scale (8-item) demonstrated good sensitivity to change following attendance of the 
FACETS programme (within participant effect sizes 0.66 and 0.69 and 0.54 at 1, 4, and 12 months follow-up). 
Principal Components Analysis yielded one component. In the Rasch analysis two items with disordered 
thresholds were rescored. Item 8 displayed differential item functioning by disability and was combined 
into a testlet with item 4, resulting in a unidimensional scale. The sample was well targeted to the scale.
Conclusion: At a scale level the Multiple Sclerosis-Fatigue Self-Efficacy scale is internally valid and has 
good sensitivity to change.
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Introduction
Fatigue is one of the most commonly reported 
symptoms of multiple sclerosis.1 It has a profound 
impact on all spheres of life,2, 3 both for the person 
with multiple sclerosis and their relatives,4 and is 
one of the key precipitants of early retirement.5, 6 
Self-efficacy, the “belief in one’s capabilities to 
organise and execute the course of action required 
to produce given attainments”7 has been identified 
as a strong predictor of health status in multiple 
sclerosis.8 It is also associated with health promot-
ing behaviours such as physical activity.9 Studies 
have shown that a higher sense of self-control pre-
dicts lower fatigue severity and chronicity,10 sug-
gesting that increasing self-efficacy related to 
fatigue could improve quality of life. Thus, self-
efficacy is an important domain to measure and 
manage actively in education, rehabilitation and 
health promotion programmes.8
A group-based fatigue management programme 
for people with multiple sclerosis, partly based on 
self-efficacy theory, has recently been evaluated in 
a randomized controlled trial.11–13 We wanted to test 
whether the intervention did improve self-efficacy. 
However, existing generic self-efficacy scales14, 15 
and multiple sclerosis specific self-efficacy 
scales16–20 do not have a focus on fatigue and thus 
may not be specific enough to measure change in 
this variable in a multiple sclerosis population.
Fatigue self-efficacy scales have been devel-
oped for other conditions. For example, in a study 
considering the effectiveness of a multi-component 
programme for chronic fatigue syndrome, 
Goudsmit et al. (2009)21 modified Lorig’s 6-item 
Self-Efficacy ‘Other Symptoms’ subscale.22 
Similarly, in the cancer field, the Perceived Self-
Efficacy for Fatigue Self-Management scale has 
been developed.23 This scale was also adapted from 
Lorig’s 6-item scale by modifying items to focus 
on fatigue.24 While the preliminary psychometric 
findings from this study suggest the Perceived 
Self-Efficacy for Fatigue Self-Management scale 
is a promising tool, it has not been validated in peo-
ple with multiple sclerosis and does not include 
items related to several domains likely to be of rel-
evance to people with multiple sclerosis fatigue, 
such as unpredictability and interference with eve-
ryday life.
For our study12 we adapted the 9-item Control 
subscale of Schwartz’s Multiple Sclerosis Self- 
Efficacy25 scale to form a new Multiple Sclerosis-
Fatigue Self-Efficacy scale. The aim of this paper 
is to report on the scale’s development and 
validation.
Methods
The Multiple Sclerosis-Fatigue Self-Efficacy scale 
was developed by altering the wording of 6 of the 
9 original Multiple Sclerosis Self-Efficacy scale 
items to make them fatigue-specific (supplemen-
tary material online Appendix). For items 2, 5 and 
6 this entailed replacing ‘multiple sclerosis’ with 
‘fatigue’ and for items 3, 4 and 9 replacing ‘multi-
ple sclerosis symptoms’ with ‘fatigue’. Items 1, 7, 
and 8 were not modified. We retained the original 
response format of the Multiple Sclerosis Self- 
Efficacy scale, which consists of a 10-point 
numeric rating scale (ranging from 10-100) with 
verbal anchors of ‘very uncertain’ (10) and ‘very 
certain’ (100) and the descriptor ‘moderately 
uncertain’, at the midpoint (spanning 50 and 60). 
A summary score is produced by taking the mean 
of the 9 items. The Multiple Sclerosis-Fatigue 
Self-Efficacy scale was administered as part of a 
questionnaire battery presented in a booklet with a 
14pt. font size.
Participants
Data from 164 participants who participated in a 
randomized controlled trial of a group-based 
fatigue management programme (FACETS)11, 12, 
26 were used to explore the validity of the Multiple 
Sclerosis-Fatigue Self-Efficacy scale. In addition, 
data from 34 participants who participated in pilot 
phases of the research were used to consider con-
vergent validity. In the full trial, outcomes were 
measured 1 week before the start of the 6-week 
FACETS programme and 1-, 4-and 12 months 
after its conclusion. Participants assigned to the 
Usual Care arm completed all outcome measures 
within an identical time frame to those in the 
FACETS arm. For a detailed description of par-
ticipants, recruitment methods, and outcome 
measures please refer to the published trial proto-
col and papers.11, 12
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Inclusion criteria were: (1) clinically definite 
diagnosis of multiple sclerosis, (2) reporting sig-
nificant fatigue impacting on daily life (score on 
the Fatigue Severity Scale > 4)27 and (3) ambula-
tory (score on the Adapted Patient Determined 
Disease Steps scale <8).28 Participants were 
excluded if they: (1) were non-English speaking, 
(2) had had a relapse requiring corticosteroids 
within the past 3 months, (3) had started a disease 
modifying drug or anti-depressant within the past 3 
months, (4) were judged by the clinical team to 
have cognitive deficits such that they could not 
engage in the group format, (5) had attended a spe-
cific fatigue management programme within the 
past year or had received a specific fatigue inter-
vention from a health professional within the previ-
ous 3 months, (6) were currently under the care of 
a psychiatrist or under the care of addiction ser-
vices, or (7) were already involved in another 
research study. Participants were recruited in three 
UK centres (Poole, Bristol, Southampton/
Portsmouth) from primary or secondary care, or 
via the UK Multiple Sclerosis Society website or 
newsletters.
Analysis
Data analysis included a consideration of score dis-
tributions and internal consistency (Cronbach’s 
Alpha and item-total correlations).29 One would 
expect that scores on the Multiple Sclerosis-Fatigue 
Self-Efficacy scale would show high associations 
with scales measuring conceptually similar con-
structs (convergent validity) but relatively lower 
associations with those less closely related (discri-
minant validity). We examined this with data from 
our pilot phase in which we administered both the 
Multiple Sclerosis Self-Efficacy scale and the 
Multiple Sclerosis-Fatigue Self-Efficacy scale 
(n=34) and with data from our main study (n=164), 
using Spearman’s Rank correlation coefficients. 
The hypothesised strength and direction of associa-
tions were as follows:
-  A strong positive correlation between the 
Multiple Sclerosis-Fatigue Self-Efficacy scale 
and the Multiple Sclerosis Self-Efficacy scale.
-  A weak positive correlation between  the 
Multiple Sclerosis-Fatigue Self-Efficacy 
scale and the SF-36 Pain subscale.
-  A moderate negative correlation between the 
Multiple Sclerosis-Fatigue Self-Efficacy 
scale and the Global Fatigue Severity sub-
scale of the Fatigue Assessment Instrument.
-  A moderate positive correlation between the 
Multiple Sclerosis-Fatigue Self-Efficacy 
scale and the SF-36 Vitality subscale.
Sensitivity to change was assessed with Cohen’s 
effect size statistic (considered large if >0.5)30 
using the mean difference from baseline at each 
follow-up point (1-, 4- and 12 months) divided 
by the baseline standard deviation. This utilised 
data from the trial for those participants who 
attended 4 or more sessions of the six week 
group-based fatigue management programme 
(FACETS).
Principal Components Analysis31 was used to 
explore dimensionality of the scale with parallel 
analysis32 used to help to determine the number of 
components to retain.
The Multiple Sclerosis-Fatigue Self-Efficacy 
scale was tested against the polytomous partial 
credit Rasch model33 to examine internal validity. 
Overall fit to the Rasch model was examined with 
an item-trait interaction Chi-square test, which 
should be non-significant. Individual person and 
item fit residuals should be within the range of -2.5 
and 2.5. Person fit and item fit statistics are trans-
formed to approximate a z-score; therefore, when 
the data fit the Rasch model, the overall distribu-
tion statistics for item fit and person fit should have 
a mean of approximately zero and standard devia-
tion close to 1.34 Log-transformed item scores gen-
erated from the items’ response choices should 
reflect an increase in the latent trait of self-efficacy 
to be measured. Thresholds are the points where 
the probabilities of a response of either 10 or 20, 
and 20 or 30 (and so forth) are equally likely and 
therefore threshold locations should be increasing 
along the trait. When a given level of fatigue self-
efficacy is not confirmed by the expected response 
option to an item, disordered thresholds will be 
observed. In such cases item categories should be 
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collapsed until they are ordered so that a more pre-
cise estimate of individuals’ fatigue self-efficacy 
can be obtained.
Differential item functioning35, 36 (or bias of the 
items) was examined with an Analysis of Variance 
with the following groups as the main factor: age, 
trial arm, educational attainment, time since diag-
nosis, marital status, current employment status 
and level of mobility. Response dependency was 
examined using a residual correlation of 0.30 
below the mean residual as an acceptable cut off.37
A key requirement of the Rasch model is that 
the scale is unidimensional. This is examined by 
creating two subsets of items, which are identified 
by a Principal Component Analysis of the item 
residuals, with those loading negatively forming 
one set and those loading positively forming the 
second set.38 Strict unidimensionality is then exam-
ined using an independent t-test on the two esti-
mates derived from the subtests for each respondent. 
If the 95% confidence interval of t-tests includes 
5%, unidimensionality is supported.38
The precision of the scale was examined with 
the Person Separation Index (similar to a 
Cronbach’s Alpha), which can range from 0 to 1.34 
Values ≥0.70 allow for group comparisons but for 
individual clinical use values should be ≥0.85. 
Testlets were created if problems with response 
dependency or differential item functioning were 
found, to test if bias is cancelled out at the test level 
and also to see if they removed the dependency in 
the data.39 Bonferroni corrections were applied to 
judge the statistical significance of findings. If the 
scale fits the Rasch model ordinal data arising from 
the scale are converted onto an interval scale using 
Rasch analysis software (RUMM2030).40
Analyses were carried out using SPSS Version 
2041 and RUMM2030.40
Ethical approval was obtained from the South 
West-Central Bristol Research Ethics Committee 
(ref: 08/H0106/2). All participants gave written 
informed consent before taking part. The trial spon-
sor was Poole Hospital NHS Foundation Trust.
Results
Participant characteristics are displayed in Table 1.
Response rate and item distributions
Baseline data on the Multiple Sclerosis-Fatigue 
Self-Efficacy scale were not available for five 
Table 1. Descriptive statistics for demographic and baseline characteristics of participants.
Participant characteristics Main study (n=164) Pilot phase (n=34)
Gender [n (%)]
Female 119 (73%) 23 (68%)
Male 45 (27%) 11 (32%)
Age (years)
Mean (SD) Range 49.0 (9.7) 23-73 46.2 (7.3) 29-59
Marital status [n (%)]
Married/cohabiting 117 (74%) 27 (79%)
Single 12 (8%) 4 (12%)
Separated/divorced 23 (15%) 3 (9%)
Widowed 5 (3%) –
Not stated 7 –
Years since diagnosis [n (%)]
<1 yr 6 (4%) 4 (13%)
1-5 yrs 53 (34%) 14 (45%)
6-10 yrs 32 (20%) 9 (29%)
11-15 yrs 33 (21%) 2 (6%)
>16 yrs 34 (21%) 2 (6%)
Not stated 6 3
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people. All response choices for the nine items 
were utilised and there was no evidence of floor or 
ceiling effects either at baseline (Table 2) or at sub-
sequent follow-up points. Item 3 had somewhat 
more missing data, mostly due to respondents not 
being able to answer as they did not know any 
other people with multiple sclerosis (6.3%). For 
this reason the remaining analyses were carried out 
with item 3 deleted, i.e. testing the 8-item scale. 
The 8-item Multiple Sclerosis-Fatigue Self-
Efficacy scale data followed a normal distribution 
pattern at baseline (n=159), 1st follow-up (n=146), 
2nd follow-up (n=144) and 3rd follow-up (n=131).
In terms of the FACETS trial data there were sta-
tistically significant differences on the 8-item 
Multiple Sclerosis-Fatigue Self-Efficacy scale 
favouring the FACETS arm over the Usual Care arm 
at 1 month (mean diff (MD) 9, 95% CI (3 to 14), 
standardised effect size (SES) 0.51, p=0.001). At 4 
months follow-up, this difference approached sig-
nificance (MD 6, 95% CI (0 to 12), SES 0.33, p = 
0.07) (Table 3) and a similar SES was obtained at one 
year (MD 5, 95% CI (-1 to 12), SES 0.30, p = 0.13).
Sensitivity to change
For those in the FACETS group who attended 4 or 
more FACETS sessions the mean Multiple 
Sclerosis-Fatigue Self-Efficacy scale total score 
improved significantly from baseline to 1 month 
follow-up (t(63) = -5.44. p < 0.001, SES = 0.66), 
from baseline to 4 months follow-up (t(61) = 
–4.77, p < 0.001, SES = 0.69) and from baseline to 
one year follow-up (t(55) = –4.07, p < 0.001, SES 
= 0.54).
Multiple Sclerosis-Fatigue Self-Efficacy 
scale dimensionality
Principal Components Analysis revealed two 
eigenvalues greater than 1.0 and the break in the 
scree plot suggested two components should be 
retained. A parallel analysis, however, indicated 
that only one was statistically significant and 
should be retained: i.e. only the first eigenvalue 
from the actual data is larger than the mean and 
95th percentile of the corresponding eigenvalue 
derived from the 1000 randomly generated data-
sets. Thus, this analysis suggests a one-factor solu-
tion explaining 56.7% of the variance (Table 4).
Internal reliability
Cronbach’s alphas were good for the Fatigue Self- 
Efficacy Scale (8 item) at all four time points: 0.89 
at baseline (n=156), 0.93 at 1 month follow-up 
(n=145), 0.94 at 4 months follow-up (n=142) and 
0.90 at 1 year follow-up (n=129). The sample size 
at each time point is slightly smaller than in previ-
ous reported analyses as Cronbach’s Alpha 
requires responses to all items. Corrected item-
total correlations (Pearson’s) were all high (>0.50) 
(Table 5). Cronbach’s Alpha would not have been 
improved had any of the items been deleted.
Table 2. Distribution of response frequencies of the Multiple Sclerosis-Fatigue Self-Efficacy scale measure (baseline 
time point data, n=159).
Item No. Numeric response rating category (frequency %)
 10 20 30 40 50 60 70 80 90 100 Missing
1 17 (11%) 16 (10%) 12 (8%) 16 (10%) 34 (21%) 33 (21%) 19 (12%) 9 (6%) 2 (1%) 1 (1%) –
2 15 (9%) 14 (9%) 25 (16%) 18 (11%) 30 (19%) 22 (14%) 18 (11%) 8 (5%) 6 (4%) 3 (2%) –
3 16 (10%) 14 (9%) 19 (12%) 14 (9%) 39 (25%) 24 (15%) 13 (8%) 5 (3%) 3 (2%) 2 (1%) 10 (6%)
4 13 (8%) 8 (5%) 21 (13%) 19 (12%) 40 (25%) 13 (8%) 17 (11%) 17 (11%) 5 (3%) 4 (3%) 2 (1%)
5 14 (9%) 11 (7%) 29 (18%) 24 (15%) 27 (17%) 20 (13%) 13 (8%) 9 (6%) 6 (4%) 6 (4%)  
6 11 (7%) 14 (9%) 36 (23%) 23 (14%) 37 (23%) 8 (5%) 11 (7%) 13 (8%) 4 (3%) 2 (1%) –
7 24 (15%) 18 (11%) 28 (18%) 31 (19%) 17 (11%) 15 (9%) 16 (10%) 7 (4%) 2 (1%) 1 (1%) –
8 15 (9%) 7 (4%) 19 (12%) 16 (10%) 33 (21%) 23 (14%) 18 11%) 17 (11%) 7 (4%) 4 (3%) –
9 17 (11%) 10 (6%) 25 (16%) 24 (15%) 31 (20%) 14 (9%) 10 (6%) 14 (9%) 7 (4%) 6 (4%) 1 (1%)
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Convergent and discriminant reliability
As expected, the Multiple Sclerosis-Fatigue Self-
Efficacy scale (8-item) had a strong positive associ-
ation with the Multiple Sclerosis Self-Efficacy scale 
(rs32 = 0.78, p < 0.001). However, it should be noted 
that the Multiple Sclerosis Self- Efficacy scale and 
Multiple Sclerosis-Fatigue Self-Efficacy scale 
(8-item version) possess three identical items (items 
1, 7 and 8). When these items were removed from 
the Fatigue Self-Efficacy Scale and a revised total 
score based on the 5 remaining items was calcu-
lated, the correlation still remained high (rs32 = 0.77, 
p <.001). The association between the Pain subscale 
from the SF-36 and the Multiple Sclerosis-Fatigue 
Self-Efficacy scale (8-item version) was low and 
non-significant (rs157= 0.11, p = 0.18). The associa-
tion with the Global Fatigue Severity subscale of the 
Fatigue Assessment Instrument was rs157 -0.33 (p = 
< 0.001) and the correlation with the Vitality sub-
scale of the SF-36 was rs157= 0.33 (p = < 0.001).
Rasch analysis
Initial fit to the Rasch model showed that two items 
had disordered thresholds (items 1 and 8) (Table 6, 
Analysis 1, Figure 1). Response categories 20 and 
30 for these two items were collapsed. Once 
Table 3. Descriptive statistics and treatment effects of the 8-item Multiple Sclerosis-Fatigue Self-Efficacy scale at 
each time point (main study)*.
 Baseline 1 month follow-up 4 months follow-up 12 months follow-up
n=159 n=146 n=144 n=131
FACETS mean (SD) 
range
45 (17) 11-85 57 (17) 13-88 56 (19) 14-89 56 (17) 10-100
USUAL CARE mean 
(SD) range
49 (16) 10-84 50 (17) 10-90 53 (17) 10-94 51 (16) 11-95
Mean diff [95% CI] – 9 (3 to 14) 6 (0 to 12) 5 (–1 to 12)
p-value – 0.001 0.07 0.13
Std effect size – 0.51 0.33 0.30
* Item 3 has been deleted from the final MS-FSE (Multiple Sclerosis-Fatigue Self Efficacy scale). The analysis was performed before 
the Rasch analysis.
Table 4. Factor loadings and total variance explained of the 8-item Multiple Sclerosis-Fatigue Self-Efficacy scale 
(baseline, n=159)*.
Component † Initial Eigenvalues Eigenvalues generated 
by Monte Carlo 
Analysis
95% percentile of 
eigenvalues generated by 
Monte Carlo analysis Total % of Variance
1 4.54 56.72 1.36 1.47
2 1.09 13.59 1.21 1.30
3 0.67 8.41 1.11 1.16
4 0.60 7.51 1.03 1.08
5 0.36 4.49 0.95 0.99
6 0.32 4.01 0.87 0.93
7 0.25 3.08 0.78 0.85
8 0.18 2.20 0.69 0.77
* The analysis was performed on the ordinal Multiple Sclerosis-Fatigue Self-Efficacy scale (i.e. before the Rasch analysis).†Extraction 
Method: Principal Component Analysis; Kaiser-Meyer-Olkin Measure of Sampling Adequacy = .85; Bartlett’s Test of Sphericity p 
< 0.001.
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Table 6. Fit of the Multiple Sclerosis-Fatigue Self-Efficacy scale to the Rasch Model.
Analysis 
number
Item fit residual Person fit residual Chi-square interaction Person separation 
index
Uni-dimensionality 
(95% CI) 
Mean SD Mean SD Value (df) p-value
1* 0.55 1.55 –0.54 1.63 20.16 (16) 0.21 0.88 10.7% (7.3 to 14.1)
2† 0.55 1.48 –0.51 1.57 17.65 (16) 0.35 0.88 11.3% (7.9 to 14.7)
3∞ –0.32 3.03** –0.60 1.01 2.069 (4) 0.72 0.88 3.8% (0.4 to 7.3)
* Fit to the Rasch model of the 8-item Multiple Sclerosis-Fatigue Self-Efficacy scale. †Two categories of items 1 and 8 have been 
collapsed to deal with reversed thresholds. ∞Item 8 has been combined into a testlet with item 4 to deal with differential item 
functioning.
**Item fit residual standard deviation may be >1.4 when unequal length testlets present44.
Figure 1. Threshold ordering item 1 (baseline data).
The top image displays the threshold ordering of item 1 and indicates a disordering – the bottom image depicts thresholds after  
response categories 20 and 30 have been collapsed resulting in ordered thresholds. (Note: the software presents the first  
response category as 0 by default and therefore response categories 10-100 are denoted in the left diagram as 0-9).
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Figure 2. Person item threshold distribution 8-item Multiple Sclerosis-Fatigue Self-Efficacy scale.
The x-axis displays the interval scale in logits, mapping the location and distribution of item thresholds on the lower part of the 
graph and of persons on the upper part of the graph.
satisfactory, data were again fitted to the Rasch 
model (Table 6, analysis 2). The data did not deviate 
significantly from the Rasch model (non-significant 
Chi-square), the mean item fit residual was accepta-
ble, items had satisfactory fit (non-significant Chi-
square statistics) although the fit residual for one 
item was above the acceptable value of 2.5 (2.73). 
However, the data were not unidimensional and there 
was response dependency between the residuals of 
items 5 and 6 and items 8 and 9.
One item displayed significant uniform differen-
tial item functioning by level of disability (item 8). 
This item was combined into a testlet with an item 
that displayed non-significant differential item 
functioning in the opposite direction (item 4), with 
the remaining 6 items combined into a second test-
let. This resulted in a unidimensional scale, with 
satisfactory fit to the Rasch model (Table 6, analy-
sis 3). The A-statistic provides an indication of the 
variance that is lost once testlets are created; in our 
case A=1.0, suggesting the two testlets explained 
the same amount of variance in the data as the origi-
nal 8-item scale.42 A person separation index of 0.92 
suggests the scale is suitable for group and individ-
ual use.34 The person-item threshold map demon-
strates a good spread of item thresholds and people 
along the construct of self-efficacy (Figure 2).
Discussion
We have adapted a widely used measure of self-
efficacy for people with multiple sclerosis to meas-
ure fatigue self-efficacy. Six percent of participants 
left item 3 blank because they felt it was not appli-
cable. Consequently, these were not data missing at 
random, which Rasch analysis could have dealt 
with, but missing in a systematic way because par-
ticipants were not able to answer the item. For this 
reason we deleted it from the 9-item scale. The 
8-item scale demonstrated low levels of missing 
data, satisfactory internal consistency, convergent 
and discriminant validity, and sensitivity to change. 
Parallel analysis indicated one component. Our 
within participant effect sizes for the Multiple 
Sclerosis-Fatigue Self-Efficacy scale were higher 
than that found for the Multiple Sclerosis Self-
Efficacy scale (0.52) in a study of a brief cognitive 
behavioural programme for people with multiple 
sclerosis.18 Similarly, our effect sizes were higher 
than that found for the Liverpool Self-Efficacy 
Scale following a lay-led self-management pro-
gramme (0.16) for people with multiple sclerosis.43 
Evidence for convergent validity was obtained 
with the Multiple Sclerosis-Fatigue Self-Efficacy 
scale correlating very highly with the most 
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conceptually similar scale, the Multiple Sclerosis 
Self-Efficacy scale, and less so with measures of 
fatigue and pain. All 8-items had corrected item-
total correlations > 0.5. Once two items (1 and 8) 
with disordered thresholds were rescored and the 
differential item functioning of item 4 was 
addressed via creation of a testlet, a unidimensional 
scale was achieved with a satisfactory fit to the 
Rasch model. This suggests that the initial lack of 
unidimensionality observed was spurious and 
driven by differential item functioning.
While other self-efficacy scales for fatigue have 
been developed 21, 23 they have not been validated 
in multiple sclerosis populations and have not 
included items related to unpredictability and inter-
ference with everyday life; domains likely to be 
highly relevant to people with multiple sclerosis. A 
strength of this study is that we have adapted an 
existing widely used scale in multiple sclerosis 
rather than developing a new measure. The 
Multiple Sclerosis-Fatigue Self-Efficacy scale 
drew upon items from Lorig’s Arthritis Self-
Efficacy scale, which in turn was developed 
through consultation with patients and physicians 
and through study of four groups of patients. This 
ensures the patient centredness of the tool. Other 
strengths include the fact that as the sample was 
part of a multi-centre RCT the numbers are rela-
tively large and include a range of disease type and 
duration. A limitation is that we do not have any 
information about those who did not wish to take 
part in the trial. Therefore, we cannot comment if 
there could be a response bias towards those with 
more self-efficacy. Another limitation is that we 
only have convergent validity data (correlating 
scores on the Multiple Sclerosis Self-Efficacy scale 
and the Multiple Sclerosis-Fatigue Self-Efficacy 
scale) on a relatively small sample (n=34) from our 
pilot work. Furthermore, we were unable to carry 
out a test-retest analysis for the Multiple Sclerosis-
Fatigue Self-Efficacy scale. Finally, the scale will 
need language and cultural validation testing prior 
to use in languages other than English.
In conclusion, the Multiple Sclerosis-Fatigue 
Self-Efficacy scale is a valid and responsive scale 
that can be used for the measurement of self-efficacy 
in people with multiple sclerosis fatigue. A conver-
sion table for converting raw scores on the Multiple 
Sclerosis-Fatigue Self-Efficacy scale to an interval 
scale is available from the authors.
Clinical message
••  The new Multiple Sclerosis-Fatigue Self-
Efficacy scale is valid and able to meas-
ure change over time in people with 
multiple sclerosis.
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